# ALNY catalysts: ALNYLAM PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alny/catalysts

> ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 20 upcoming catalysts. The next is the brezosiran trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ALNY?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 20 upcoming catalysts. The next is the brezosiran trial start, 2027. Press release filed with the SEC (EX-99): "− Presented Positive Phase 1 Data for Brezosiran (ALN-HTT02) Demonstrating Robust Target Engagement and Encouraging Safety and Tolerability Profile in Patients with Huntington's Disease; Expect to Initiate Pivotal Study in 2027 -" [Calendar and source filings](https://sec-api.dev/companies/alny/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001178670-26-000074, https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/companies/alny/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ALNYLAM PHARMACEUTICALS, INC. |
| Ticker | ALNY (Nasdaq) |
| SEC CIK | 1178670 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/alny |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [Mivelsiran trial start](https://sec-api.dev/pdufa/mivelsiran) | ALNY | early-onset AD, and in April 2023 and July 2023, we reported positive interim results | completed | "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm)) |
| Apr 2023 | [Mivelsiran interim data readout](https://sec-api.dev/pdufa/mivelsiran) | ALNY | early-onset AD, and in April 2023 and July 2023, we reported positive interim results | completed, positive | "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm)) |
| Sep 2023 | [Zilebesiran topline data readout](https://sec-api.dev/pdufa/zilebesiran) | ALNY |  | completed, positive | "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of the development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years, as consideration for Blackstone Life Sciences' funding for Phase 2 clinical development costs of zilebesiran." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| September 13, 2023 | [ONPATTRO® (patisiran) FDA advisory committee meeting](https://sec-api.dev/pdufa/patisiran) | ALNY |  | completed, positive | "The committee will discuss supplemental new drug application (sNDA) 210922-s015, for ONPATTRO (patisiran) lipid complex for injection, submitted by Alnylam Pharmaceuticals, Inc., for the proposed treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-september-13-2023-cardiovascular-and-renal-drugs-advisory)) |
| Oct 2023 | [ONPATTRO® (patisiran) complete response letter (CRL)](https://sec-api.dev/pdufa/patisiran) | ALNY |  | completed, complete response letter | "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a complete response letter in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| Mar 2024 | [Zilebesiran topline data readout](https://sec-api.dev/pdufa/zilebesiran) | ALNY |  | completed, positive | "In March 2024, we reported positive topline results from our KARDIA-2 clinical trial, which is designed to evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm)) |
| Apr 2024 | [Zilebesiran trial start](https://sec-api.dev/pdufa/zilebesiran) | ALNY |  | completed | "In April 2024, we dosed the first patient in our KARDIA-3 Phase 2 clinical trial, which is designed to evaluate the efficacy and safety of zilebesiran as an add-on therapy in adult patients with high cardiovascular risk and uncontrolled hypertension despite treatment with two to four standard of care antihypertensive medications, and we expect to report results from the KARDIA-3 Phase 2 clinical trial in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm)) |
| Jun 2024 | [AMVUTTRA® (vutrisiran) topline data readout](https://sec-api.dev/pdufa/vutrisiran) | ALNY | ATTR amyloidosis with cardiomyopathy | completed, positive | "In June 2024, we reported positive topline results from the HELIOS-B clinical trial of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| Jul 2024 | [Mivelsiran trial start](https://sec-api.dev/pdufa/mivelsiran) | ALNY | CAA and in July 2026, we | completed | "In July 2024, we initiated the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA and in July 2026, we announced that we had completed enrollment in this trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| October 9, 2024 | [AMVUTTRA® (vutrisiran) NDA/BLA submission](https://sec-api.dev/pdufa/vutrisiran) | ALNY |  | completed | "On October 9, 2024, we announced that we had filed a supplemental New Drug Application, or sNDA, with the United States Food and Drug Administration, or the FDA, using a Priority Review Voucher." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| Nov 2024 | [Nucresiran interim data readout](https://sec-api.dev/pdufa/nucresiran) | ALNY | ATTR amyloidosis | completed, positive | "In November 2024, we announced positive interim results from the Phase 1 clinical trial of nucresiran, our next generation investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis which utilizes our IKARIA technology, demonstrating rapid knockdown of TTR that was sustained for six months following a single dose." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm)) |
| Nov 2024 | [AMVUTTRA® (vutrisiran) NDA/BLA acceptance](https://sec-api.dev/pdufa/vutrisiran) | ALNY |  | completed | "In November 2024, the FDA accepted our sNDA submission for review for vutrisiran, with an action date set for March 23, 2025 under the Prescription Drug User Fee Act, or PDUFA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| 1H 2025 | [Elebsiran trial start](https://sec-api.dev/pdufa/elebsiran) | ALNY |  | scheduled | "Vir has also evaluated elebsiran in combination with tobevibart for the treatment of chronic hepatitis D virus, or CHD, and Vir expects to initiate a Phase 3 registrational study to evaluate the combination of elebsiran and tobevibart in CHD in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| 1H 2025 | [Nucresiran trial start](https://sec-api.dev/pdufa/nucresiran) | ALNY | ATTR amyloidosis with cardiomyopathy | scheduled | "We expect to initiate the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR amyloidosis with cardiomyopathy in the first half of 2025, and expect to initiate the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR polyneuropathy in late 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm)) |
| January 12, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm)) |
| March 20, 2025 | [AMVUTTRA® (vutrisiran) FDA approval](https://sec-api.dev/pdufa/vutrisiran) | ALNY | ATTR Amyloidosis with Cardiomyopathy | completed, approved | "Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm)) |
| March 20, 2025 | [AMVUTTRA® (vutrisiran) label expansion decision](https://sec-api.dev/pdufa/vutrisiran) | ALNY | cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis | completed, approved | "CAMBRIDGE, Mass. -- Mar. 20, 2025—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm)) |
| March 23, 2025 | [AMVUTTRA® (vutrisiran) PDUFA date](https://sec-api.dev/pdufa/vutrisiran) | ALNY | with ATTR amyloidosis with cardiomyopathy | completed, approved | "** Guidance assumes FDA approval of the sNDA for vutrisiran for the treatment of adults with ATTR amyloidosis with cardiomyopathy by the March 23, 2025 PDUFA target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm)) |
| March 23, 2025 | [ALNYLAM PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | scheduled | "▪The FDA has accepted the sNDA and set an action goal date of March 23, 2025, under PDUFA" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| June 19, 2025 | [Zilebesiran primary completion](https://sec-api.dev/pdufa/zilebesiran) | ALNY | High Cardiovascular Risk; Hypertension | completed | "NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06272487)) |
| 2H 2025 | [Zilebesiran trial start](https://sec-api.dev/pdufa/zilebesiran) | ALNY |  | scheduled | "We plan to announce topline results from KARDIA-3, and to initiate a Phase 3 cardiovascular outcomes trial of zilebesiran, in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| July 31, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/alny2025q2earningsrelease.htm)) |
| Sep 2025 | [Nucresiran trial start](https://sec-api.dev/pdufa/nucresiran) | ALNY |  | completed | "In September 2025, we initiated the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR amyloidosis with polyneuropathy, or hATTR-PN, and in June 2025, we initiated the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR-CM." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| Sep 2025 | [Zilebesiran trial start](https://sec-api.dev/pdufa/zilebesiran) | ALNY | uncontrolled hypertension | completed | "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| Q4 2025 | [Mivelsiran trial start](https://sec-api.dev/pdufa/mivelsiran) | ALNY |  | scheduled | "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm)) |
| Oct 2025 | [Brezosiran trial start](https://sec-api.dev/pdufa/brezosiran) | ALNY | HD and in October 2026 reported positive initial clinical trial results | completed | "In October 2025, we initiated a Phase 1b clinical trial of brezosiran in adult patients with HD and in October 2026 reported positive initial clinical trial results and announced that we plan to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment, to evaluate the ability of brezosiran to slow disease progression in adults living with HD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| October 30, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny2025q3earningsrelease.htm)) |
| January 11, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/alny2026q1exhibit991.htm)) |
| February 12, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny2025q4earningsrelease.htm)) |
| April 30, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny2026q1earningsrelease.htm)) |
| July 30, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny2026q2earningsrelease.htm)) |
| Q4 2026 | [Elebsiran topline data readout](https://sec-api.dev/pdufa/elebsiran) | ALNY |  | scheduled | "Vir is currently evaluating elebsiran in combination with tobevibart in multiple clinical trials as part of its ongoing ECLIPSE registrational program, including the ECLIPSE 1 Phase 3 clinical trial in CHD, which is fully enrolled with topline data expected in the fourth quarter of 2026, the ECLIPSE 2 Phase 3 clinical trial, which is evaluating the switch to the combination of elebsiran and tobevibart in patients who have not achieved undetectable hepatitis delta virus RNA with bulevirtide treatment, and the ECLIPSE 3 Phase 2b trial, which is evaluating the combination of elebsiran and tobevibart compared to bulevirtide monotherapy in bulevirtide treatment-naive patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm)) |
| October 29, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)) |
| 2027 | [Brezosiran trial start](https://sec-api.dev/pdufa/brezosiran) | ALNY | Huntington's Disease | scheduled | "− Presented Positive Phase 1 Data for Brezosiran (ALN-HTT02) Demonstrating Robust Target Engagement and Encouraging Safety and Tolerability Profile in Patients with Huntington's Disease; Expect to Initiate Pivotal Study in 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)) |
| May to Aug 2027 | [ALN-4324 topline data readout](https://sec-api.dev/pdufa/aln-4324) | ALNY | Type 2 Diabetes Mellitus (T2DM) | scheduled | "NCT07465224 (A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465224)) |
| May 2027 | [ALN-4324 primary completion](https://sec-api.dev/pdufa/aln-4324) | ALNY | Type 2 Diabetes Mellitus (T2DM) | scheduled | "NCT07465224 (A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465224)) |
| Jun to Sep 2027 | [ALN-6400 topline data readout](https://sec-api.dev/pdufa/aln-6400) | ALNY | Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) | scheduled | "NCT07575308 (HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575308)) |
| June 2027 | [ALN-6400 primary completion](https://sec-api.dev/pdufa/aln-6400) | ALNY | Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) | scheduled | "NCT07575308 (HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575308)) |
| Aug to Nov 2027 | [Aln-app topline data readout](https://sec-api.dev/pdufa/aln-app) | ALNY | Cerebral Amyloid Angiopathy | scheduled | "NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06393712)) |
| August 2027 | [Aln-app primary completion](https://sec-api.dev/pdufa/aln-app) | ALNY | Cerebral Amyloid Angiopathy | scheduled | "NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06393712)) |
| Dec 2027 to Mar 2028 | [Nucresiran topline data readout](https://sec-api.dev/pdufa/nucresiran) | ALNY | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN | scheduled | "NCT07223203 (TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223203)) |
| December 2027 | [Nucresiran primary completion](https://sec-api.dev/pdufa/nucresiran) | ALNY | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN | scheduled | "NCT07223203 (TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223203)) |
| 2028 | [ALNYLAM PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | scheduled | "◦Topline results are expected in 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny2025q3earningsrelease.htm)) |
| Mar to Jun 2028 | [AMVUTTRA® (vutrisiran) topline data readout](https://sec-api.dev/pdufa/vutrisiran) | ALNY | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | scheduled | "NCT06679946 (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679946)) |
| March 2028 | [AMVUTTRA® (vutrisiran) primary completion](https://sec-api.dev/pdufa/vutrisiran) | ALNY | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | scheduled | "NCT06679946 (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679946)) |
| April 2028 | [Aln-agt01 rvr primary completion](https://sec-api.dev/pdufa/aln-agt01-rvr) | ALNY | Hypertension | scheduled | "NCT07553442 (A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-01 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553442)) |
| Apr to Jul 2028 | [Aln-agt01 rvr topline data readout](https://sec-api.dev/pdufa/aln-agt01-rvr) | ALNY | Hypertension | scheduled | "NCT07553442 (A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-01 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553442)) |
| May to Aug 2030 | [Nucresiran topline data readout](https://sec-api.dev/pdufa/nucresiran) | ALNY | Transthyretin Amyloidosis With Cardiomyopathy | scheduled | "NCT07052903 (TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07052903)) |
| May to Aug 2030 | [Mivelsiran topline data readout](https://sec-api.dev/pdufa/mivelsiran) | ALNY | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | scheduled | "NCT07636811 (A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07636811)) |
| May 2030 | [Mivelsiran primary completion](https://sec-api.dev/pdufa/mivelsiran) | ALNY | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | scheduled | "NCT07636811 (A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07636811)) |
| May 2030 | [Nucresiran primary completion](https://sec-api.dev/pdufa/nucresiran) | ALNY | Transthyretin Amyloidosis With Cardiomyopathy | scheduled | "NCT07052903 (TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07052903)) |
| Sep to Dec 2030 | [Zilebesiran topline data readout](https://sec-api.dev/pdufa/zilebesiran) | ALNY | High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk | scheduled | "NCT07181109 (Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07181109)) |
| September 2030 | [Zilebesiran primary completion](https://sec-api.dev/pdufa/zilebesiran) | ALNY | High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk | scheduled | "NCT07181109 (Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07181109)) |

## Drugs

- [ALN-4324](https://sec-api.dev/pdufa/aln-4324): Type 2 Diabetes Mellitus (T2DM)
- [ALN-6400](https://sec-api.dev/pdufa/aln-6400): Von Willebrand Disease (VWD)
- [Aln-agt01 rvr](https://sec-api.dev/pdufa/aln-agt01-rvr): Hypertension
- [Aln-app](https://sec-api.dev/pdufa/aln-app): Cerebral Amyloid Angiopathy
- [Brezosiran](https://sec-api.dev/pdufa/brezosiran): huntington's disease, hd and in october 2026 reported positive initial clinical trial results
- [Mivelsiran](https://sec-api.dev/pdufa/mivelsiran): early-onset ad, and in april 2023 and july 2023, we reported positive interim results, caa and in july 2026, we, Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- [Nucresiran](https://sec-api.dev/pdufa/nucresiran): attr amyloidosis, attr amyloidosis with cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, Transthyretin Amyloidosis With Cardiomyopathy
- [ONPATTRO® (patisiran)](https://sec-api.dev/pdufa/patisiran): attr amyloidosis with cardiomyopathy
- [AMVUTTRA® (vutrisiran)](https://sec-api.dev/pdufa/vutrisiran): cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, attr amyloidosis with cardiomyopathy, with attr amyloidosis with cardiomyopathy, Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- [Zilebesiran](https://sec-api.dev/pdufa/zilebesiran): uncontrolled hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alny/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALNY catalysts: ALNYLAM PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alny/catalysts

```bibtex
@misc{secapidev_companies_alny_catalysts_20261116,
  title        = {ALNY catalysts: ALNYLAM PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alny/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alny_catalysts_20261116","title":"ALNY catalysts: ALNYLAM PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alny/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
